Related Experiment Video

Updated: Dec 14, 2025

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.6K

Long Noncoding RNAs in Atherosclerosis and Vascular Injury: Pathobiology, Biomarkers, and Targets for Therapy

Jacob B Pierce1,2, Mark W Feinberg1

  • 1From the Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (J.B.P., M.W.F.).

Arteriosclerosis, Thrombosis, and Vascular Biology
|July 24, 2020
PubMed

Insights

Long noncoding RNAs (lncRNAs) are key epigenetic regulators in atherosclerosis and restenosis after vascular injury. This review explores their roles, mechanisms, biomarker potential, and therapeutic strategies for cardiovascular disease.

Area of Science:

  • Molecular Biology
  • Cardiovascular Research
  • Epigenetics

Background:

  • Atherosclerotic cardiovascular disease poses a significant global health and economic burden.
  • Vascular restenosis after percutaneous coronary interventions limits treatment effectiveness.
  • Long noncoding RNAs (lncRNAs) are emerging as critical epigenetic regulators in vascular disease.

Purpose of the Study:

  • To review the role of lncRNAs in atherosclerosis development.
  • To examine lncRNAs' contribution to restenosis following vascular injury.
  • To discuss lncRNA mechanisms, biomarker utility, and therapeutic potential.

Main Methods:

  • Literature review of lncRNAs in atherosclerosis and restenosis.
  • Analysis of intracellular regulatory mechanisms of lncRNAs.
  • Evaluation of lncRNAs as biomarkers and therapeutic targets.

Main Results:

  • lncRNAs play crucial roles in regulating atherosclerosis and restenosis.
  • Diverse intracellular mechanisms underlie lncRNA function in vascular pathology.
  • lncRNAs show promise as biomarkers and therapeutic targets.

Conclusions:

  • lncRNAs are significant epigenetic regulators in cardiovascular disease.
  • Targeting lncRNAs offers potential therapeutic strategies for atherosclerosis and restenosis.
  • Further research into lncRNA mechanisms and applications is warranted.

Keywords:
atherosclerosisbiomarkerscardiovascular diseasesoligonucleotidespercutaneous coronary intervention

More Related Videos

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.6K
A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium11:00

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium

Published on: June 22, 2010

29.4K

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
596
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.2K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
748
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
261
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
251